A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.

Chang Gon Kim Min Hee Hong Da Hee Kim Brian Hyohyoung Lee Hyunwook Kim Chan-Young Ock Geoffrey Kelly Yoon Ji Bang Gamin Kim Jung Eun Lee Chaeyeon Kim Se-Heon Kim Hyun Jun Hong Young Min Park Nam Suk Sim Heejung Park Jin Woo Park Chang Geol Lee Kyung Hwan Kim Goeun Park Inkyung Jung Dawoon Han Jong Hoon Kim Junha Cha Hoyoung Lee Mingu Kang Heon Song Chiyoon Oum Seulki Kim Sukjun Kim Yoojoo Lim Seunghee Kim-Schulze Miriam Merad Sun Och Yoon Hyun Je Kim Yoon Woo Koh Hye Ryun Kim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Preoperative D±T is feasible and may benefit patients with resectable HNSCC. Distinct changes in the tumor microenvironment and circulating immune cells were induced by each treatment regimen, warranting further investigation.

Keyphrases

phase ii
open label
clinical trial
patients undergoing
phase iii
double blind
locally advanced
phase ii study
study protocol
placebo controlled
squamous cell carcinoma
randomized controlled trial
radiation therapy
combination therapy